Samsara BioCapital LLC Has $603,000 Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Samsara BioCapital LLC decreased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,263 shares of the company's stock after selling 11,263 shares during the quarter. Samsara BioCapital LLC's holdings in Janux Therapeutics were worth $603,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JANX. Adage Capital Partners GP L.L.C. boosted its position in shares of Janux Therapeutics by 47.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock valued at $163,926,000 after acquiring an additional 986,750 shares during the period. Price T Rowe Associates Inc. MD grew its position in Janux Therapeutics by 596.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock worth $59,429,000 after purchasing an additional 950,557 shares during the last quarter. FMR LLC grew its position in Janux Therapeutics by 10.8% in the 4th quarter. FMR LLC now owns 8,669,941 shares of the company's stock worth $464,189,000 after purchasing an additional 845,266 shares during the last quarter. Lord Abbett & CO. LLC increased its holdings in shares of Janux Therapeutics by 80.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,267,803 shares of the company's stock worth $67,878,000 after purchasing an additional 564,322 shares during the period. Finally, Wellington Management Group LLP raised its position in shares of Janux Therapeutics by 3,592.9% during the fourth quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock valued at $28,665,000 after buying an additional 520,898 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Insider Transactions at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. bought 341,742 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was bought at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the purchase, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the transaction, the insider now owns 82,139 shares in the company, valued at $2,464,170. The trade was a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,335 shares of company stock valued at $454,959 in the last three months. 29.40% of the stock is owned by corporate insiders.

Janux Therapeutics Stock Performance

Shares of NASDAQ:JANX traded up $0.83 on Friday, hitting $32.88. The stock had a trading volume of 825,257 shares, compared to its average volume of 848,137. The firm's 50 day moving average price is $29.80 and its 200-day moving average price is $42.57. Janux Therapeutics, Inc. has a twelve month low of $22.52 and a twelve month high of $71.71. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -28.10 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on JANX shares. Scotiabank lowered their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. Wedbush restated an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.